Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones

3 Sept 2014

Abstract excerpt

The efficacy of gemcitabine (GEM), a standard treatment agent for pancreatic cancer, is insufficient because of primary or acquired resistance to this drug. Patients with tumors intrinsically sensitive to GEM gradually acquire resistance and require a shift to second agents, which are associated with the risk of cross-resistance. However, whether cross-resistance is actually present has long been disputed. Using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to Pancreatic and Hepatic Oncology Research
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25187316
DOI: 10.1097/cad.0000000000000165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clonesPMID 25187316Read ↗

Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell linesSemantic proximity Read ↗

Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virusSemantic proximity Read ↗

Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.Semantic proximity Read ↗

Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cellsSemantic proximity Read ↗

Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.Semantic proximity Read ↗

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.Semantic proximity Read ↗

Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracilSemantic proximity Read ↗

[Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].Semantic proximity Read ↗

Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.Semantic proximity Read ↗

Diversity of multidrug resistance in mammalian cells.Semantic proximity Read ↗

Mitomycin C cross-resistance induced by adriamycin in human ovarian cancer cells in vitro.Semantic proximity Read ↗

C6 cells cross-resistant to cisplatin and radiation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.